K.N. TAZHIBAYEVA^1-4, A.D. SADYKOVA^1-4, S.T. OLZHAEV², B.Zh. ADZHIBAEV², A.A. MUSSINA⁵, M.M. KHASSANOVA², K.K. BAIMUKHAMETOV², M.M. АDIYEV²

1. «Al-Farabi Kazakh National University» NPJSC, Almaty, the Republic of Kazakhstan;
2. SCE on LEA «Almaty Regional Multidisciplinary Clinic», Almaty region, the Republic of Kazakhstan;
3. «CAPHRI» Maastricht University» SU, Maastricht, the Netherlands;
4. «Asfendiyarov Kazakh National Medical University» NCJSC, Almaty, the Republic of Kazakhstan;
5. «Astana Medical University» NPJSC, Astana, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2024-1-71-57-64

UDC: 618.14-006.6

Year: 2024 issure: 71 number: 1 pages: 57-64

Download PDF:

ABSTRACT

Relevance: Ovarian preservation in young women with early-stage endometrial cancer after surgical treatment has been conventionally associated with complications. Nevertheless, recent randomized studies suggest a different perspective.
The study aimed to clarify the occurrence of complications, in particular relapses, associated with ovarian preservation in young women after hormonal and surgical treatment for early-stage endometrial cancer.
Methods: The analysis included articles published in full text over the past 10 years. We identified relevant observations from studies using a comprehensive search in the following databases: PubMed, Medline, Embase, and Cochrane Library. The search strategy included terms related to endometrial cancer: premenopausal, young woman, endometrial cancer, ovarian conservation. The study followed the PRISMA guidelines for systematic reviews.
Results: A total of 178 articles were studied, of which 111 articles (literature reviews and meta-analyses) (62%) described the cases of ovarian preservation. Of these, 84 were excluded for various reasons; 29 eligible articles were included in this analysis. Notably, factors such as younger age (P<0.0001) >, later year of diagnosis (P=0.03), residence in Central and Southern Europe and the United States (P=0.02), and lower-grade tumors in Asian countries (P<0.002) > correlated with the desire of women to preserve their ovaries. The conducted literature review showed that ovarian preservation did not significantly affect cancer-specific survival (risk ratio (HR) =0.78, 95% CI 0.17-2.74) or overall survival (HR=0.78, 95% CI 0.24-1.75).
This study’s results remained practically unchanged even after excluding women after radiation and hormone therapy.
Conclusion: This literature review revealed no statistically significant difference in relapse-free survival between patients after ovarian preservation at stage IA and partially at stage II com-pared to those after bilateral salpingo-oophorectomy.
Keywords: Ovarian preservation, endometrial cancer, recurrence-free survival, lymphadenectomy, premenopausal women.

List of sources used:

1. Gonthier C., Trefoux-Bourdet A., Koskas M. Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium // Int. J. Gynecol. Cancer. – 2017. – Vol. 27(3). – P. 493-499. https://doi.org/10.1097/IGC.0000000000000895
2. Matsuo K., Machida H., Shoupe D., Melamed A., Muderspach L.I., Roman L.D., Wright J.D. Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer // Obstet. Gynecol. – 2016. – Vol. 128(4). – P. 761-770. https://doi.org/10.1097/AOG.0000000000001647
3. Obermair A., Baxter E., Brennan D.J., McAlpine J.N., Muellerer J.J., Amant F. Fertility-sparing treatment in early endometrial cancer: current state and future strategies // Obstet. Gynecol. Sci. – 2020. – Vol. 63. – P. 417–431. https://doi.org/10.5468/ogs.19169
4. Wang Yong-xue., JIN Ying;L Ya. Safety and prognosis of ovarian preservation in young women with early-stage endometrial cancer // Clin. Med. – 2017. – Vol. (04). – P. 443-447. https://doi.org/10.11969%2Fj.issn.1673-548X.2016.07.017
5. Cappelletti E., Humann J., Torrejón R., Gambadauro P. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis // Hum. Reprod. Upd. – 2022. – Vol. 28. – P. 282-295. https://doi.org/10.1093/humupd/dmab041
6. Atallah D., El Kassis N., Safi J., El Hachem H., Chahine G., Moubarak M. The use of hysteroscopic endometrectomy in the conservative treatment of early endometrial cancer and atypical hyperplasia in fertile women // Arch. Gynecol. Obstet. – 2021. – Vol. 304(5). – P. 1299-1305. https://doi.org/10.1007/s00404-021-06048-0
7. Ayhan A., Tohma Y.A., Tunc M. Fertility preservation in early-stage endometrial cancer and endometrial intraepithelial neoplasia: A single-center experience // Taiwan J. Obstet. Gynecol. – 2020. – Vol. 59(3). – P. 415-419. https://doi.org/10.1016/j.tjog.2020.03.014
8. Chen M., Jin Y., Li Y., Bi Y., Shan Y., Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer // Int. J. Gynaecol. Obstet. – 2016. – Vol. 132(1). – P. 34. https://doi.org/10.1016/j.ijgo.2015.06.046
9. Falcone F., Laurelli G., Losito S., Di Napoli M., Granata V., Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer // J. Gynecol. Oncol. – 2017. – Vol. 28(1). – P. 12. https://doi.org/10.3802/jgo.2017.28.e2
10. Raffone A., Travaglino A., Flacco M.E., Iasevoli M., Mollo A., Guida M., Insabato L., Di Spiezio Sardo A., Carugno J., Zullo F. Clinical Predictive Factors of Response to Treatment in Patients Undergoing Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer // J. Adolesc. Young Adult. Oncol. – 2021. – Vol. 10(2). –193-201. https://doi.org/10.1089/jayao.2020.0100
11. Tamauchi S., Kajiyama H., Utsumi F., Suzuki S., Niimi K., Sakata J., Mizuno M., Shibata K., Kikkawa F. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer // J. Obstet. Gynaecol. Res. – 2018. – Vol. 44(1). – P. 151-156. https://doi.org/10.1111/jog.13473
12. Tock S., Jadoul P., Squifflet J.L., Marbaix E., Baurain J.F., Luyckx M. Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature // Front. Med (Lausanne). – 2018. – Vol. 27. – P. 240. https://doi.org/10.3389/fmed.2018.00240
13. Moher D., Liberati A., Tetzlaff J., Altman D.G., The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement // PLoS Med. – 2009. – Vol. 6(7). – Art. no.: e1000097. https://doi.org/10.1371/journal.pmed1000097
14. Wright J.D., Buck A.M., Shah M., Burke W.M., Schiff P.B., Herzog T.J. Safety of ovarian preservation in premenopausal women with endometrial cancer // J. Clin. Oncol. – 2009. – Vol. 27(8). – P. 214-219. https://doi.org/10.1200/JCO.2008.19.8150
15. Casadio P., Guasina F., Paradisi R., Leggieri C., Caprara G., Seracchioli R. Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study // Oncologist. – 2018. – Vol. 23(4). – P. 478-480. https://doi.org/10.1634/theoncologist.2017-0285
16. Casadio P., La Rosa M., Alletto A., Magnarelli G., Arena A., Fontana E., Fabbri M., Giovannico K., Virgilio A., Raimondo D., Guasina F., Paradisi R., Seracchioli R. Fertility Sparing Treatment of Endometrial Cancer with and without Initial Infiltration of Myometrium: A Single Center Experience // Cancers (Basel). – 2020. – Vol. 29 (12). – P. 3571. https://doi.org/10.3390/cancers12123571
17. Giampaolino P, Di Spiezio Sardo A., Mollo A., Raffone A., Travaglino A., Boccellino A., Zizolfi B., Insabato L., Zullo F., De Placido G., Bifulco G. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study // J. Minim. Invasive Gynecol. – 2019. – Vol. 26(4). – P. 648-656. https://doi.org/10.1016/j.jmig.2018.07.001
18. Gungor T., Cetinkaya N., Yalcin H., Zergeroglu S., Erkaya S. Clinicopathologic characteristics and treatment features of women with the incidental diagnosis of endometrial adenocarcinoma during infertility follow-up in Ankara, Turkey // J. Obstet. Gynecol. – 2016. – Vol. 55(3). – P. 309. https://doi.org/10.1016/j.tjog.2016.04.003
19. Maggiore U., Martinelli F., Dondi G., Bogani G., Chiappa V., Evangelista MT., Liberale V., Ditto A., Ferrero S., Raspagliesi F. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study // J. Gynecol. Oncol. – 2019. – Vol. 30(4). – P. 57. https://doi.org/10.3802/jgo.2019.30.e57
20. Ohyagi-Hara C., Sawada K., Aki I., Mabuchi S., Kobayashi E., Ueda Y., Yoshino K., Fujita M., Tsutsui T., Kimura T. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature // Arch. Gynecol. Obstet. – 2015. – Vol. 291(1). – P. 151. https://doi.org/10.1007/s00404-014-3417-z
21. Wang C.J., Chao A., Yang L.Y., Hsueh S., Huang Y.T., Chou H.H., Chang T.C., Lai CH. Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study // Int. J. Gynecol. Cancer. – 2015. – Vol. 24(4). – P. 718-28. https://doi.org/10.1097/IGC.0000000000000098
22. Wang F., Yu A., Xu H., Zhang X., Li L., Lou H., Yu H., Lin J. Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma // Int. J. Gynecol. Cancer. – 2017. – Vol. 27(9). – P. 1919-1925. https://doi.org/10.1097/IGC.0000000000001109
23. Yang H.C., Liu J.C., Liu F.S. Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy // Taiwan J. Obstet. Gynecol. – 2019. – Vol. 58(1). – P. 90-93. https://doi.org/10.1016/j.tjog.2018.11.017
24. Zhang Z., Huang H., Feng F., Wang J., Cheng N. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer // J. Gynecol. Oncol. – 2019. – Vol. 30(4). – P. 61. https://doi.org/10.3802/jgo.2019.30.e61
25. Gallup D.G., Stock R.J. Adenocarcinoma of the endometrium in women 40 years of age or younger // Obstet. Gynecol. – 2014. – Vol. 64. – P. 417-420. https://doi.org/10.1038/s41574-022-00725-z
26. Nasioudis D., Chapman-Davis E., Frey M., Holcomb K. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma // J. Gynecol. Oncol. –2017. – Vol. 28(4). – P. 46. https://doi.org/10.3802/jgo.2017.28.e46
27. Shin W., Park S.Y., Kang., The survival effect of ovary preservation in early-stage endometrial cancer: a single institution retrospective analysis // J. Ovarian Res. – 2020. – Vol. 97. – P. 13. https://doi.org/10.1186/s13048-020-00698-5
28. Lyu T., Guo L., Chen X., Jia N., Gu C., Zhu M. Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study // J. Int. Med. Res. – 2019. – Vol. 47(6). – P. 2492-2498. https://doi.org/10.1177/0300060518822432
29. Akgor U., Ayhan A., Shushkevich A., Ozdal B., Angelou K., Akbayır O., Kaidarova D., Ulrikh E., Stepanyan A., Ortac F., Aliyev S., Ozgul N., Taranenka S., Haberal A., Salman C., Seyhan A., Selcuk I., Haidopoulos D., Akıllı H., Bolatbekova R., Alaverdyan A., Taskin S., Murshudova S., Batur M., Berlev I., Gultekin M. An international multicenter study of ovarian preservation in endometrial cancers // Gynaecol. Obstet. – 2022. – Vol. 159(2). – P. 550-556. https://doi.org/10.1002/ijgo.14190
30. Shen F., Chen S., Gao Y., Dai X., Chen Q. The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women // Oncotarget. – 2017. – Vol. 46. – P. 89-94. https://doi.org/10.18632/oncotarget.20384
31. Xu J., Chen C., Xiong J., Wang H., Linghu H. Predictive Value of Serum Cytokeratin 19 Level for the Feasibility of Conserving Ovaries in Endometrial Cancer // Medicine. – 2021. – Vol. 5. – P. 109. https://doi.org/10.3389/fmed.2021.670109
32. Wang J., Li XM. Meta-analysis of prognosis of ovarian preserving in young patients with early endometrial cancer // Zhonghua Fu Chan Ke Za Zhi. – 2016. – Vol. 25 (8). – P. 602-607 [In Chinese]. https://doi.org/10.3760/cma.j.issn.0529-567X.2016.08.010
33. Jia P., Zhang Y. Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer // Oncotarget. – 2017. – Vol. 8. – P. 59940-59949. https://doi.org/10.18632/oncotarget.18404
34. Berek J.S., Matias-Guiu X. FIGO Endometrial Cancer Staging Subcommittee, FIGO Women’s Cancer Committee. Response: FIGO staging of endometrial cancer 2023 // Int. J. Gynaecol. Obstet. – 2023. – Vol. 163(1). – P. 331-331. https://doi.org/10.1002/ijgo.15046